Personalized Vaccine for Patients With Recurrent Malignant Glioma

Inclusion Criteria: * age 18-70; * signed inform consent; * patients with recurrent malignant glioma; have received surgery, radiotherapy, chemotherapy; * patients' tumor tissue should have a high mutation load(\>10 TMB); be genetically unstable; at least have 10 neoantigens; * should be able to provide tumor tissue and peripheral blood for sequencing and flow cytometry analysis; * at least three months post last operation; one month after the completion of the last anti-drug therapy or radiotherapy; * have not received any immune therapy; * at least have one measurable lesion; * KPS \>60; * estimated survival \> 3 months * patients should have adequate organ and bone marrow function; Exclusion Criteria: * female patient is breastfeeding or pregnant; * known history of allergy to peptides or other stimulating factors (i.e. GM-CSF); * known history of Graft-Versus-Host Disease (GVHD); * participation in gene therapy; * other malignancy; * systemic disease: i.e., severe infection; HIV; * other conditions upon investigator's judgement;